Glioblastomas (GBMs) are the most aggressive primary brain tumors, with an average survival of less than 15 months. Therefore, there is a critical need to develop novel therapeutic strategies for GBM. This study aimed to assess the prognostic value of miR-4516 and investigate its oncogenic functions and the underlying cellular and molecular mechanisms in GBM. To determine the correlation between miR-4516 expression and overall survival of patients with GBM, total RNAs were isolated from 268 FFPE tumor samples, miR expression was assayed (simultaneously) using the nCounter human miRNA v3a assay followed by univariable and multivariable survival analyses. Further, in vitro and in vivo studies were conducted to define the role of miR-4516 in GBM tumorigenesis and the underlying molecular mechanisms. Upon multivariable analysis, miR-4516 was correlated with poor prognosis in GBM patients (HR = 1.49, 95%CI: 1.12–1.99, P = 0.01). Interestingly, the significance of miR-4516 was retained including MGMT methylation status. Overexpression of miR-4516 significantly enhanced cell proliferation and invasion of GBM cells both in vitro and in vivo. While conducting downstream targeting studies, we found that the tumor-promoting function of miR-4516, in part, was mediated by direct targeting of PTPN14 (protein tyrosine phosphatase, non-receptor type 14) which, in turn, regulated the Hippo pathway in GBM. Taken together, our data suggest that miR-4516 represents an independent negative prognostic factor in GBM patients and acts as a novel oncogene in GBM, which regulates the PTPN14/Hippo pathway. Thus, this newly identified miR-4516 may serve as a new potential therapeutic target for GBM treatment.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. Neuro Oncol. 2015;17(Suppl 4):iv1–iv62.

  2. 2.

    Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27:836–52.

  3. 3.

    Lenos K, Grawenda AM, Lodder K, Kuijjer ML, Teunisse AF, Repapi E, et al. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer. Cancer Res. 2012;72:4074–84.

  4. 4.

    Zougman A, Hutchins GG, Cairns DA, Verghese E, Perry SL, Jayne DG, et al. Retinoic acid-induced protein 3: identification and characterisation of a novel prognostic colon cancer biomarker. Eur J Cancer. 2013;49:531–9.

  5. 5.

    He L, Hannon GJ. MicroRNAs: small RNAs with a big role in gene regulation. Nat Rev Genet. 2004;5:522–31.

  6. 6.

    Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM. MicroRNA expression and function in cancer. Trends Mol Med. 2006;12:580–7.

  7. 7.

    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834–8.

  8. 8.

    Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastas Rev. 2009;28:369–78.

  9. 9.

    Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol. 2007;302:1–12.

  10. 10.

    Xia H, Yan Y, Hu M, Wang Y, Wang Y, Dai Y, et al. MiR-218 sensitizes glioma cells to apoptosis and inhibits tumorigenicity by regulating ECOP-mediated suppression of NF-kappaB activity. Neuro Oncol. 2013;15:413–22.

  11. 11.

    Li S, Zeng A, Hu Q, Yan W, Liu Y, You Y. miR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in glioblastomas. Neuro Oncol. 2017;19:55–65.

  12. 12.

    Chang W, Liu M, Xu J, Fu H, Zhou B, Yuan T, et al. MiR-377 inhibits the proliferation of pancreatic cancer by targeting Pim-3. Tumour Biol. 2016;37:14813–24.

  13. 13.

    Du W, Liu X, Chen L, Dou Z, Lei X, Chang L, et al. Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. Neuro Oncol. 2015;17:243–53.

  14. 14.

    Belle L, Ali N, Lonic A, Li X, Paltridge JL, Roslan S, et al. The tyrosine phosphatase PTPN14 (Pez) inhibits metastasis by altering protein trafficking. Sci Signal. 2015;8:ra18.

  15. 15.

    Laczmanska I, Sasiadek MM. Tyrosine phosphatases as a superfamily of tumor suppressors in colorectal cancer. Acta Biochim Pol. 2011;58:467–70.

  16. 16.

    Liu X, Yang N, Figel SA, Wilson KE, Morrison CD, Gelman IH, et al. PTPN14 interacts with and negatively regulates the oncogenic function of YAP. Oncogene. 2013;32:1266–73.

  17. 17.

    Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, et al. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget. 2015;6:5932–46.

  18. 18.

    Chowdhari S, Saini N. hsa-miR-4516 mediated downregulation of STAT3/CDK6/UBE2N plays a role in PUVA induced apoptosis in keratinocytes. J Cell Physiol. 2014;229:1630–8.

  19. 19.

    Michaloglou C, Lehmann W, Martin T, Delaunay C, Hueber A, Barys L, et al. The tyrosine phosphatase PTPN14 is a negative regulator of YAP activity. PLoS ONE. 2013;8:e61916.

  20. 20.

    Wang W, Huang J, Wang X, Yuan J, Li X, Feng L, et al. PTPN14 is required for the density-dependent control of YAP1. Genes Dev. 2012;26:1959–71.

  21. 21.

    Pan D. The hippo signaling pathway in development and cancer. Dev Cell. 2010;19:491–505.

  22. 22.

    Yu FX, Zhao B, Guan KL. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell. 2015;163:811–28.

  23. 23.

    Zhao B, Li L, Lei Q, Guan KL. The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 2010;24:862–74.

  24. 24.

    Varelas X. The Hippo pathway effectors TAZ and YAP in development, homeostasis and disease. Development. 2014;141:1614–26.

  25. 25.

    Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

  26. 26.

    McNamara MG, Sahebjam S, Mason WP. Emerging biomarkers in glioblastoma. Cancers. 2013;5:1103–19.

  27. 27.

    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.

  28. 28.

    Bell EH, Kirste S, Fleming JL, Stegmaier P, Drendel V, Mo X, et al. A novel miRNA-based predictive model for biochemical failure following post-prostatectomy salvage radiation therapy. PLoS ONE. 2015;10:e0118745.

  29. 29.

    Borrelli N, Denaro M, Ugolini C, Poma AM, Miccoli M, Vitti P, et al. miRNA expression profiling of 'noninvasive follicular thyroid neoplasms with papillary-like nuclear features' compared with adenomas and infiltrative follicular variants of papillary thyroid carcinomas. Mod Pathol. 2017;30:39–51.

  30. 30.

    Wilson KE, Li YW, Yang N, Shen H, Orillion AR, Zhang J. PTPN14 forms a complex with Kibra and LATS1 proteins and negatively regulates the YAP oncogenic function. J Biol Chem. 2014;289:23693–700.

  31. 31.

    Team RC. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2016.

  32. 32.

    Bady P, Sciuscio D, Diserens AC, Bloch J, van den Bent MJ, Marosi C, et al. MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status. Acta Neuropathol. 2012;124:547–60.

  33. 33.

    Maksimovic J, Gordon L, Oshlack A. SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol. 2012;13:R44.

  34. 34.

    Fortin JP, Triche TJ Jr, Hansen KD. Preprocessing, normalization and integration of the Illumina HumanMethylationEPIC array with minfi. Bioinformatics. 2017;33:558–60.

  35. 35.

    Cui T, Chen Y, Yang L, Knosel T, Huber O, Pacyna-Gengelbach M, et al. The p53 target gene desmocollin 3 acts as a novel tumor suppressor through inhibiting EGFR/ERK pathway in human lung cancer. Carcinogenesis. 2012;33:2326–33.

  36. 36.

    Han C, Zhao R, Liu X, Srivastava A, Gong L, Mao H, et al. DDB2 suppresses tumorigenicity by limiting the cancer stem cell population in ovarian cancer. Mol Cancer Res. 2014;12:784–94.

  37. 37.

    Cui T, Srivastava AK, Han C, Yang L, Zhao R, Zou N, et al. XPC inhibits NSCLC cell proliferation and migration by enhancing E-Cadherin expression. Oncotarget. 2015;6:10060–72.

  38. 38.

    Wong N, Wang X. miRDB: an online resource for microRNA target prediction and functional annotations. Nucleic Acids Res. 2015;43(Database issue):D146–52.

  39. 39.

    Agarwal V, Bell GW, Nam JW, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. eLife. 2015;4:e05005. https://doi.org/10.7554/eLife.05005

  40. 40.

    Hsu SD, Lin FM, Wu WY, Liang C, Huang WC, Chan WL, et al. miRTarBase: a database curates experimentally validated microRNA-target interactions. Nucleic Acids Res. 2011;39(Database issue):D163–9.

  41. 41.

    Benjamini Y, Hochberg Y. Controlling the false discovery rate - a practical and powerful approach to multiple testing. J Roy Stat Soc B Met. 1995;57:289–300.

Download references


We thank the T&P Bohnenn Fund for Neuro-Oncology Research (grant to P.A.R.), the Ohio State University (OSU) Comprehensive Cancer Center Small Animal Imaging Core, and the Ohio State University (OSU) Comprehensive Cancer Center Pathology Core Facility supported in part by grant P30 CA016058, National Cancer Institute, Bethesda, MD.


This work was supported by National Cancer Institute [R01CA169368 (to A.C.), R01CA11522358 (to A.C.), R01CA1145128 (to A.C.), R01CA108633 (to A.C.), R01CA188228 (to A.C., R.B., K.L., and J.B.), 1RC2CA148190 (to A.C.), and U10CA180850–01 (to A.C.)]; A Brain Tumor Funders Collaborative Grant (to A.C.); Ohio State University Comprehensive Cancer Center Award (to A.C.).

Author information

Author notes

  1. These authors contributed equally: Tiantian Cui, Erica H. Bell


  1. Department of Radiation Oncology, Arthur G. James Hospital/Ohio State Comprehensive Cancer Center, Columbus, OH, 43210, USA

    • Tiantian Cui
    • , Erica H. Bell
    • , Aline Paixao Becker
    • , Pooja Manchanda Gulati
    • , Linlin Yang
    • , Ziyan Liu
    • , Jessica L. Fleming
    • , S. Jaharul Haque
    •  & Arnab Chakravarti
  2. Department of Biomedical Informatics, The Ohio State University Center for Biostatistics, Columbus, OH, USA

    • Joseph McElroy
  3. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands

    • Marjolein Geurts
    •  & Pierre Robe
  4. Department of Internal Medicine, Division of Nephrology, Columbia University, New York, NY, 10032, USA

    • Nikol Mladkova
  5. The Ohio State University, Columbus, OH, 43210, USA

    • Ashley Gray
  6. The Ohio State University College of Medicine, Columbus, OH, 43210, USA

    • Kevin Liu
  7. Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA

    • Jill S. Barnholtz-Sloan
  8. Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA

    • Keith L. Ligon
  9. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

    • Keith L. Ligon
    •  & Rameen Beroukhim
  10. Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, 02215, USA

    • Rameen Beroukhim


  1. Search for Tiantian Cui in:

  2. Search for Erica H. Bell in:

  3. Search for Joseph McElroy in:

  4. Search for Aline Paixao Becker in:

  5. Search for Pooja Manchanda Gulati in:

  6. Search for Marjolein Geurts in:

  7. Search for Nikol Mladkova in:

  8. Search for Ashley Gray in:

  9. Search for Kevin Liu in:

  10. Search for Linlin Yang in:

  11. Search for Ziyan Liu in:

  12. Search for Jessica L. Fleming in:

  13. Search for S. Jaharul Haque in:

  14. Search for Jill S. Barnholtz-Sloan in:

  15. Search for Keith L. Ligon in:

  16. Search for Rameen Beroukhim in:

  17. Search for Pierre Robe in:

  18. Search for Arnab Chakravarti in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Arnab Chakravarti.

Supplementary information

About this article

Publication history